LIMN (Liminatus Pharma) Total Payout Ratio: 1.29 (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LIMN Liminatus Pharma Inc LIMN
13 GF Score
Price $0.10
! 1 Warning Sign
View Full Analysis

What is Liminatus Pharma Total Payout Ratio?

Liminatus Pharma LIMN -5.81% 13 Total Payout Ratio is 1.29 as of Aug. 06, 2026. GuruFocus rates LIMN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Liminatus Pharma's current Total Payout Ratio is 1.29.

Liminatus Pharma Total Payout Ratio Related Terms

Liminatus Pharma Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Liminatus Pharma's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liminatus Pharma Total Payout Ratio Chart

Liminatus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
1.20 0.00 0.00 1.03

Liminatus Pharma Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -93.43 0.00 0.00 3.19

LIMN vs BRTX, BOLT, TRAW: Total Payout Ratio Comparison

For the Biotechnology subindustry, Liminatus Pharma's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Liminatus Pharma Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liminatus Pharma's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Liminatus Pharma's Total Payout Ratio falls into.


LIMN
13GF Score
Liminatus Pharma Inc LIMN
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Liminatus Pharma Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Liminatus Pharma's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 10.557 + 0) / -10.207
=1.03

Liminatus Pharma's Total Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (3.585 + 0 + 0) / -1.124
=3.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 1.29 mean?
Liminatus Pharma (LIMN) has a Total Payout Ratio of 1.29 as of Aug. 06, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Liminatus Pharma and its competitors.
Is Liminatus Pharma's Total Payout Ratio too high?
Liminatus Pharma's current Total Payout Ratio is 1.29. Overall, Liminatus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Liminatus Pharma's Total Payout Ratio compare to BRTX and BOLT?
Liminatus Pharma's Total Payout Ratio of 1.29 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Liminatus Pharma and its competitors. Liminatus Pharma's current Total Payout Ratio is 1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current Total Payout Ratio of 1.29. The current Total Payout Ratio is 1.29. Liminatus Pharma's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current Total Payout Ratio is 1.29 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Liminatus Pharma Business Description

Address 12611 Hiddencreek Way, Unit C, Cerritos, CA, USA, 90703
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score

Get the complete analysis for LIMN

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price